IN THE CLAIMS

Please cancel claims 84 through 149 and add the following new claims 150 through 205 . The new claims add no new subject matter and are fully supported by the application, including the specification, figures, and claims as originally filed. Thus, claims 150 through 205 (55 total claims) are pending upon entry of this amendment.

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-149 (Canceled)

Claim 150 (new): A recombinant cell, comprising:

a first nucleic acid molecule comprising:

a promoter or enhancer operable for a nucleic acid molecule encoding CYP3A4, and

a reporter gene,

wherein said promoter or enhancer is operably linked to said reporter gene;

further wherein said promoter or enhancer is native to said CYP3A4; and

a second nucleic acid encoding PXR, wherein when said PXR is bound with, associated with or activated by a compound that induces the expression of said CYP3A4, said PXR can operably bind with, associate with or activate said promoter or enhancer resulting in the expression of said reporter gene;

wherein said first nucleic acid molecule, said second nucleic acid molecule, or both are stably transfected into said recombinant cell;

wherein said recombinant cell is an isolated cell or a cultured cell; and

wherein when said cell is contacted with said compound, said reporter gene is expressed.

Claim 151 (new): The recombinant cell of claim 150, wherein said promoter or enhancer comprises PXRE.

Claim 152 (new): The recombinant cell of claim 150, wherein said promoter or enhancer comprises XREM.

Claim 153 (new): The recombinant cell of claim 150, wherein said promoter or enhancer comprises PXRE and XREM.

Claim 154 (new): The recombinant cell of claim 150, wherein said reporter gene encodes an enzyme.

Claim 155 (new): The recombinant cell of claim 150, wherein said reporter gene encodes a detectable protein.

Claim 156 (new): The recombinant cell of claim 150, wherein said first nucleic acid molecule is present in an extrachromosomal element.

Claim 157 (new): The recombinant cell of claim 150, wherein said first nucleic acid molecule is within the chromosome of said cell.

Claim 158 (new): The recombinant cell of claim 150, wherein said reporter gene is inserted into the chromosome of said cell.

Claim 159 (new): The recombinant cell of claim 150, wherein said enhancer or promoter is endogenous to the chromosome of said cell.

Claim 160 (new): The recombinant cell of claim 150, wherein said reporter gene is endogenous to the chromosome of said cell.

Claim 161 (new): The recombinant cell of claim 150, wherein said PXR forms a complex with or is indirectly activated by a drug and directly or indirectly produces transcriptional activation of said nucleic acid molecule encoding CYP3A4.

Claim 162 (new): The recombinant cell of claim 150, wherein said PXR forms a complex with or is indirectly activated by a chemical and directly or indirectly produces transcriptional activation of said nucleic acid molecule encoding CYP3A4.

Claim 163 (new): The recombinant cell of claim 150, wherein said PXR forms a complex with or is indirectly activated by a metabolite and directly or indirectly produces transcriptional activation of said nucleic acid molecule encoding CYP3A4.

Claim 164 (new): The recombinant cell of claim 150, wherein said second nucleic acid molecule is present in an extrachromosomal element.

Claim 165 (new): The recombinant cell of claim 150, wherein said second nucleic acid molecule is present within the chromosome of said cell.

Claim 166 (new): The recombinant cell of claim 150, wherein said second nucleic acid molecule is endogenous to the chromosome of said cell.

Claim 167 (new): The recombinant cell of claim 150, wherein said cell is a mammalian cell.

Claim 168 (new): The recombinant cell of claim 150, wherein said cell is an isolated cell.

Claim 169 (new): The recombinant cell of claim 150, wherein said cell is a cultured cell.

Claim 170 (new): The recombinant cell of claim 150, wherein said cell is a human cell.

Claim 171 (new): The recombinant cell of claim 150, wherein said cell is a cell line.

Claim 172 (new): The recombinant cell of claim 150, wherein said cell is from liver tissue.

Claim 173 (new): The recombinant cell of claim 150, wherein said cell is from gastrointestinal tract tissue.

Claim 174 (new): The recombinant cell of claim 150, wherein said cell is from lung tissue.

Claim 175 (new): The c recombinant cell of claim 150, wherein said cell is from kidney tissue.

Claim 176 (new): A method for evaluating compounds for the property of inducing the expression of a gene encoding a protein involved in drug metabolism, comprising;
providing a test compound;
contacting a test compound with a recombinant cell comprising:
a first nucleic acid molecule comprising:
a promoter or enhancer operable for a nucleic acid molecule encoding CYP3A4, and
a reporter gene,

wherein said CYP3A4 is operably linked to said reporter gene, further wherein said promoter or enhancer is native to said CYP3A4, and

a second nucleic acid encoding PXR, wherein when said PXR is bound with, associated with or activated by a compound that induces the expression of said CYP3A4, said PXR can operably bind with, associate with or activate said promoter or enhancer resulting in the expression of said reporter gene;

wherein said recombinant cell is an isolated cell or a cultured cell;

wherein when said recombinant cell is contacted with said test compound, said reporter

gene is expressed; and

detecting the expression of said reporter gene;

wherein expression of said reporter gene is indicative that said test compound altered the expression of a gene encoding CYP3A4.

Claim 177 (new): The method of claim 176, wherein said first nucleic acid molecule is stably transfected into said recombinant cell.

Claim 178 (new): The method of claim 176, wherein said second nucleic acid molecule is stably trasfected into said recombinant cell.

Claim 179 (new): The method of claim 176, wherein said first nucleic acid molecule and said second nucleic acid molecule are stably transfected into said recombinant cell.

Claim 180 (new): The method of claim 176, wherein said method is a high throughput method.

Claim 181 (new): The method of claim 176, wherein said promoter or enahncer comprises PXRE.

Claim 182 (new): The method of claim 176, wherein said promoter or enhancer comprises XREM.

Claim 183 (new): The method of claim 176, wherein said promoter or enhancer comprises PXRE and XREM.

Claim 184 (new): The method of claim 176, wherein said reporter gene encodes an enzyme.

Claim 185 (new): The method of claim 176, wherein said reporter gene encodes a detectable protein.

Claim 186 (new): The method of claim 176, wherein said first nucleic acid molecule is present in an extrachromosomal element.

Claim 187 (new): The method of claim 176, wherein said first nucleic acid molecule is within the chromosome of said cell.

Claim 188 (new): The method of claim 176, wherein said reporter gene is inserted into the chromosome of said cell.

Claim 189 (new): The method of claim 176, wherein said enhancer or promoter is endogenous to the chromosome of said cell.

Claim 190 (new): The method of claim 176, wherein said reporter gene is endogenous to the chromosome of said cell.

Claim 191 (new): The method of claim 176, wherein said PXR forms a complex with or is indirectly activated by a drug and directly or indirectly produces transcriptional activation of a gene encoding CYP3A4.

Claim 192 (new): The method of claim 176, wherein said PXR forms a complex with or is indirectly activated by a chemical and directly or indirectly produces transcriptional activation of a gene encoding CYP3A4.

Claim 193 (new): The method of claim 176, wherein said PXR forms a complex with or is indirectly activated by a metabolite and directly or indirectly produces transcriptional activation of CYP3A4.

Claim 194 (new): The method of claim 176, wherein said second nucleic acid molecule is present in an extrachromosomal element.

Claim 195 (new): The method of claim 176, wherein said second nucleic acid molecule is present within the chromosome of said recombinant cell.

Claim 196 (new): The method of claim 176, wherein said second nucleic acid molecule is endogenous to the chromosome of said recombinant cell.

Claim 197 (new): The method of claim 176, wherein said recombinant cell is a mammalian cell.

Claim 198 (new): The method of claim 176, wherein said recombinant cell is an isolated cell.

Claim 199 (new): The method of claim 176, wherein said recombinant cell is a cultured cell.

Claim 200 (new): The method of claim 176, wherein said recombinant cell is a human cell.

Claim 201 (new): The method of claim 176, wherein said recombinant cell is a cell line.

Claim 202 (new): The method of claim 176, wherein said recombinant cell is from liver tissue.

Claim 203 (new): The cell of claim 176, wherein said recombinant cell is from gastrointestinal tract tissue.

Claim 204 (new): The cell of claim 176, wherein said recombinant cell is from lung tissue.

Claim 205 (new): The cell of claim 176, wherein said recombinant cell is from kidney tissue.